Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melanotan II as adjunct to NB-UVB in stable nonsegmental vitiligo
NCT07437560Phase 2Recruiting
- Sponsor
- Hudson Biotech
- Start
- Feb 2026
- Primary completion
- Feb 2027
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of Melanotan II in nonsegmental vitiligo (NSV), sponsored by Hudson Biotech. Started Feb 2026; status: recruiting.
02
Drugs
Melanotan II
03
Conditions
nonsegmental vitiligo (NSV)
Beyond the preview
Go deeper on NCT07437560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07437560.